Top Tweets for #Checkmate9ER
An integrative analysis of circulating and tumor microenvironment determinants of patient response in the #CheckMate9ER trial of nivolumab and cabozantinib in advanced #RenalCellCarcinoma. Presentation by @BraunMDPhD @YaleMed. #ASCO25 written coverage by @RKSayyid @USC > https://t.co/VEPnElWHrc @ASCO
💫Kidney Clinical Science Symposium #ASCO25
👉Abs4511: Dr @BraunMDPhD presenting analysis of circulating 🩸and TME 🔬 for response to Cabo/Nivo on #CheckMate9ER
🩺Clinical implications:
- Cabo/Nivo responses enriched in TME w/ high VICM anti-tumor macrophage), high PD-L1, high plasma, and low circulating Treg
Further Reading
📖 Biomarker-informed care for patients with renal cell carcinoma @mb_mckinnon @DrScottHaake
🔗 https://t.co/lcyLc5zMLU
--------------------------------------------------------
n = 150 (23% of ITT)
🧫 PD-L1 staining
🩸 4 PBMC markers
🔬 4 ECM markers
🔬 7 H&E HIF features.
♦️ECM marker VICM (fragment of vimentin measures macrophage activity and immune status) was prognostic across both therapies.
♦️Log regression models that integrated highly informatic features had AUCs of 0.76 for NIVO+CABO model and 0.72 for the SUN model.
NIVO+CABO arm determinants of response
✅high VICM (anti-tumor macrophage polarization)
✅high PD-L1
✅high plasma cell #
✅high cancer cell # at the epithelial stromal interface
👇low circulating (Pro-C6)
👇low % circulating Treg (Foxp3+ CD4+)
👥@DrChoueiri @montypal @KKellySci @tompowles1 @brian_rini @BraunMDPhD @HHammersMD @PBarataMD @PavlosMsaouel @yekeduz_emre @DrYukselUrun @ReneeSaliby @drenriquegrande @bavilima @DRBakaloudiMD @nataliagandur @crisbergerot @kidneycan @KidneyCancer @ASCO @oncoalert @OncBrothers
🔥CheckMate 9ER: Nova era no carcinoma renal com @nataliagandur!
✅+42% de redução no risco de progressão/morte
✅Sobrevivência global: 46,5 meses
✅Taxa de resposta: 55,7%
📲Leia mais: https://t.co/svFjnS5kCC
#Oncologia #CheckMate9ER #ASCOGU25 #CarcinomaRenal
Nivolumab + cabozantinib vs sunitinib for previously untreated advanced #RenalCellCarcinoma: Final follow-up results from the #CheckMate9ER trial. Presentation by @motzermd @MSKCancerCenter. #GU25 written coverage by @RKSayyid @USC > https://t.co/fRiA9xSD0S
@Larvol Quick Takes: At @ASCO - #GU25, Speaking to @brunolarvol, Dr. @DrYukselUrun talks about CheckMate 9ER trial.
#LARVOL #GUCancer #CheckMate9ER #Oncology #CancerResearch
Final #CheckMate9ER results (5+ yr FU: N+C > S in 1L #aRCC
PFS HR 0.58, OS HR 0.79, ORR 55.7% vs 27.4%. No new safety signals. N+C remains a SOC for untreated aRCC.
@ASCO #GU25 @motzermd @tompowles1 @MSKCancerCenter @OncoAlert
#GU25 @DanaFarber researchers present groundbreaking findings in #GUCancer! @DrChoueiri @VincentWenxinXu
🔹 New HIF-2α inhibitor shows promise in #RCC
🔹 KIM-1 as a biomarker for monitoring post-immunotherapy
🔹 Final follow-up of #CheckMate9ER confirms long-term benefit of nivolumab + cabozantinib
📅 Feb 13-15 | #KidneyCancer #Immunotherapy @ASCO #ASCOGU25
#ReadNow Details on UroToday > https://t.co/sAe7d35fej
🔬 Exciting insights from #CheckMate9ER! @CaPsurvivorship @DanaFarber interviews @BraunMDPhD @YaleCancer on novel glycoproteomic biomarkers for #KidneyCancer. Key findings: higher glycosylation linked to worse outcomes, and specific glycosylation events may predict response to Nivolumab + Cabozantinib. Promising steps toward new biomarker strategies! #WatchNow > https://t.co/C5u6OzctXt
🔬 Exciting insights from #CheckMate9ER! @CaPsurvivorship @DanaFarber interviews @BraunMDPhD @YaleCancer on novel glycoproteomic biomarkers for #KidneyCancer. Key findings: higher glycosylation linked to worse outcomes, and specific glycosylation events may predict response to Nivolumab + Cabozantinib. Promising steps toward new biomarker strategies! #WatchNow > https://t.co/C5u6OzctXt
🔬 Exciting insights from #CheckMate9ER! @CaPsurvivorship @DanaFarber interviews @BraunMDPhD @YaleCancer on novel glycoproteomic biomarkers for #KidneyCancer. Key findings: higher glycosylation linked to worse outcomes, and specific glycosylation events may predict response to Nivolumab + Cabozantinib. Promising steps toward new biomarker strategies! #WatchNow > https://t.co/C5u6OzctXt
🔬 Exciting insights from #CheckMate9ER! @CaPsurvivorship @DanaFarber interviews @BraunMDPhD @YaleCancer on novel glycoproteomic biomarkers for #KidneyCancer. Key findings: higher glycosylation linked to worse outcomes, and specific glycosylation events may predict response to Nivolumab + Cabozantinib. Promising steps toward new biomarker strategies! #WatchNow > https://t.co/C5u6OzctXt
🔬 Exciting insights from #CheckMate9ER! @CaPsurvivorship @DanaFarber interviews @BraunMDPhD @YaleCancer on novel glycoproteomic biomarkers for #KidneyCancer. Key findings: higher glycosylation linked to worse outcomes, and specific glycosylation events may predict response to Nivolumab + Cabozantinib. Promising steps toward new biomarker strategies! #WatchNow > https://t.co/C5u6OzctXt
Novel serum glycoproteomic biomarkers predict response to nivolumab + cabozantinib vs sunitinib in advanced #RCC: analysis from #CheckMate9ER. Presentation by @BraunMDPhD @YaleCancer. #ESMO24 written coverage by @chavarriagaj > https://t.co/OuXoSSTxcf
#CheckMate9ER gives a ✔️ to potential novel #biomarker in assessing #advanced #RCC treatment in new #ESMO24 #data from @BraunMDPhD 📈.
🔎 Learn more: https://t.co/snyUjgOggw
Excellent analysis by our very own @CharleneMantia of survival states over 4 years in #CheckMate9ER comparing 1L Nivo + Cabo vs. Sun in pts w/ aRCC! #ASCO24
➡️ Over the 4-year period since initiation of 1L therapy, the longer OS with Nivo+Cabo was accompanied by 1.5 times longer mTFS before 2L therapy vs. Sun (7 vs 4.6 mo).
@ASCO @DanaFarber_GU @OncoAlert
Cabozantinib and nivolumab combination therapy show durable efficacy in advanced #KidneyCancer. María Bourlon, MD, MSc joins @PBarataMD @caseccc to discuss #CheckMate9ER 55-month follow-up, revealing the enduring benefits of cabo + nivo over sunitinib > https://t.co/LGHMGkjsOo
Cabozantinib and nivolumab combination therapy show durable efficacy in advanced #KidneyCancer. María Bourlon, MD, MSc joins @PBarataMD @caseccc to discuss #CheckMate9ER 55-month follow-up, revealing the enduring benefits of cabo + nivo over sunitinib > https://t.co/LGHMGkjsOo
Cabozantinib and nivolumab combination therapy show durable efficacy in advanced #KidneyCancer. María Bourlon, MD, MSc joins @PBarataMD @caseccc to discuss #CheckMate9ER 55-month follow-up, revealing the enduring benefits of cabo + nivo over sunitinib > https://t.co/LGHMGkjsOo
🌟 Catch our latest video with @tompowles1 discussing #KEYNOTE564, #CheckMate9ER, and more #RCC updates! 🌟 Watch now: https://t.co/6YKg13QoJ5
A panel featuring Drs. @DrRanaMcKay, Nizar Tannir, @katy_beckermann, and @HHammersMD highlighted the #CheckMate9ER study and implications for clinical practice in #RCC. Watch Now: https://t.co/GGSCUmRall
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
240.6M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.7M followers
Cristiano Ronaldo
@cristiano
110.5M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.6M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
90.9M followers
KATY PERRY
@katyperry
87.6M followers
Taylor Swift
@taylorswift13
81.4M followers
Lady Gaga
@ladygaga
73M followers
Virat Kohli
@imvkohli
69.8M followers
Kim Kardashian
@kimkardashian
69.8M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
63.9M followers
Neymar Jr
@neymarjr
62.5M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.9M followers
X
@x
60.8M followers
Selena Gomez
@selenagomez
60.7M followers